PBA
ORKA

Paradigm Biocapital Advisors’s Oruka Therapeutics ORKA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114M Buy
2,320,316
+610,000
+36% +$21.2M 2.33% 14
2025
Q4 		$51.8M Buy
+1,710,316
New +$47.7M 1.32% 19
2025
Q1 		– Sell
-819,660
Closed -$15.9M – 34
2024
Q4 		$15.9M Buy
819,660
+100,000
+14% +$2.44M 0.55% 27
2024
Q3 		$17.6M Buy
+719,660
New +$25M 0.6% 31

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Biocapital Advisors's ORKA Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Oruka Therapeutics (ORKA) stake by 36% in Q1 2026, buying an estimated $21.2M and bringing the position to 2,320,316 shares worth $114M. The position accounts for 2.33% of the portfolio, ranked #14.

Paradigm Biocapital Advisors first reported a position in ORKA in Q3 2024 and has held it in 4 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Paradigm Biocapital Advisors held 2,320,316 shares of Oruka Therapeutics worth $114M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 610,000 Oruka Therapeutics shares in Q1 2026, an estimated $21.2M.
  • Oruka Therapeutics made up 2.33% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #14 holding.
  • Paradigm Biocapital Advisors first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.